Factors associated with viral rebound among COVID-19 patients receiving oral antivirals [PDF]
Journal of the Formosan Medical Association, 2023 Background: COVID-19 rebound is usually reported among patients experiencing concurrent symptomatic and viral rebound. But longitudinal viral RT-PCR results from early stage to rebound of COVID-19 was less characterized.
Pao-Yu Chen +17 more
doaj +4 more sources
Multidrug-resistant HIV viral rebound during early syphilis: a case report [PDF]
BMC Infectious Diseases, 2020 Background Syphilis has been associated with an increase in HIV RNA and a temporary decline in CD4 T cell counts in people living with HIV who are not receiving antiretroviral treatment (ART), and may be associated with a transient HIV RNA rebound in ...
Andrea Giacomelli +4 more
doaj +6 more sources
Viral rebound and safety of nirmatrelvir/ritonavir for lung-transplant recipients infected with SARS-CoV-2 [PDF]
Biosafety and Health, 2023 Data on the viral rebound and safety of nirmatrelvir/ritonavir in lung transplant (LTx) recipients are limited. The study prospectively followed four LTx recipients.
Hui Li +8 more
doaj +2 more sources
TLR7 agonist, N6-LS and PGT121 delayed viral rebound in SHIV-infected macaques after antiretroviral therapy interruption. [PDF]
PLoS Pathogens, 2021 Toll-like receptor 7 (TLR7) agonist and PGT121 (broadly neutralizing antibody, bnAb) administration previously delayed viral rebound and induced SHIV remission.
Denise C Hsu +17 more
doaj +2 more sources
HIV envelope antibodies and TLR7 agonist partially prevent viral rebound in chronically SHIV-infected monkeys. [PDF]
PLoS Pathogens, 2022 A key challenge for the development of a cure to HIV-1 infection is the persistent viral reservoir established during early infection. Previous studies using Toll-like receptor 7 (TLR7) agonists and broadly neutralizing antibodies (bNAbs) have shown ...
Brian Moldt +13 more
doaj +2 more sources
Impact of antiretroviral therapy in primary HIV infection on natural killer cell function and the association with viral rebound and HIV DNA following treatment interruption [PDF]
Frontiers in Immunology, 2022 Natural Killer (NK) cells play a key role in controlling HIV replication, with potential downstream impact on the size of the HIV reservoir and likelihood of viral rebound after antiretroviral therapy (ART) cessation.
Matthew Pace +24 more
doaj +2 more sources
Increased risk of virologic rebound in patients on antiviral therapy with a detectable HIV load <48 copies/mL. [PDF]
PLoS ONE, 2012 We investigated the independent effects of HIV-1 "target not detected" measurements versus those that were detectable but below the limit of quantification by Taqman RT-PCR assay on subsequent viral rebound as there are conflicting data regarding the ...
Timothy J Henrich +2 more
doaj +6 more sources
HIV viral suppression and risk of viral rebound in patients on antiretroviral therapy: a two- year retrospective cohort study in Northern Tanzania [PDF]
BMC Infectious DiseasesBackground The world is moving towards the third target of the Joint United Nations Programme on HIV/AIDS to ensure most people receiving antiretroviral therapy (ART) are virologically suppressed.
Monica S Kahabuka +6 more
doaj +2 more sources
Assessing the impact of autologous virus neutralizing antibodies on viral rebound time in postnatally SHIV-infected ART-treated infant rhesus macaques [PDF]
EpidemicsWhile the benefits of early antiretroviral therapy (ART) initiation in perinatally infected infants are well documented, early initiation is not always possible in postnatal pediatric HIV infections.
Ellie Mainou +17 more
doaj +2 more sources
Evaluating predictive markers for viral rebound and safety assessment in blood and lumbar fluid during HIV-1 treatment interruption [PDF]
, 2020 Background: Validated biomarkers to evaluate HIV-1 cure strategies are currently lacking, therefore requiring analytical treatment interruption (ATI) in study participants.
De Langhe, Nele +15 more
core +1 more source